CN106478811B - Giant knotweed frog protease inhibitory peptide, gene thereof and application thereof in pharmacy - Google Patents
Giant knotweed frog protease inhibitory peptide, gene thereof and application thereof in pharmacy Download PDFInfo
- Publication number
- CN106478811B CN106478811B CN201610915371.1A CN201610915371A CN106478811B CN 106478811 B CN106478811 B CN 106478811B CN 201610915371 A CN201610915371 A CN 201610915371A CN 106478811 B CN106478811 B CN 106478811B
- Authority
- CN
- China
- Prior art keywords
- rana
- inhibitory peptide
- protease
- protease inhibitory
- rugulosa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 79
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 75
- 108091005804 Peptidases Proteins 0.000 title claims abstract description 67
- 239000004365 Protease Substances 0.000 title claims abstract description 67
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title claims abstract 15
- 108090000623 proteins and genes Proteins 0.000 title abstract description 23
- 244000153955 Reynoutria sachalinensis Species 0.000 title description 2
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 title description 2
- 241000149471 Hoplobatrachus rugulosus Species 0.000 claims abstract description 46
- 239000003814 drug Substances 0.000 claims abstract description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 18
- 150000001413 amino acids Chemical class 0.000 claims abstract description 15
- 241000270959 Pelophylax nigromaculatus Species 0.000 claims abstract description 13
- 229920001184 polypeptide Polymers 0.000 claims abstract description 13
- 239000002773 nucleotide Substances 0.000 claims abstract description 11
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 11
- 235000018417 cysteine Nutrition 0.000 claims abstract description 9
- 235000001014 amino acid Nutrition 0.000 claims abstract description 5
- 244000000010 microbial pathogen Species 0.000 claims abstract description 4
- 238000002360 preparation method Methods 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 9
- 239000002537 cosmetic Substances 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 244000063299 Bacillus subtilis Species 0.000 claims description 6
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 6
- 241000222122 Candida albicans Species 0.000 claims description 6
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 6
- 241000191967 Staphylococcus aureus Species 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 229940095731 candida albicans Drugs 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000007760 free radical scavenging Effects 0.000 claims description 5
- IBSGMIPRBMPMHE-IHRRRGAJSA-N Leu-Met-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(O)=O IBSGMIPRBMPMHE-IHRRRGAJSA-N 0.000 claims description 4
- BCYUHPXBHCUYBA-CUJWVEQBSA-N Thr-Ser-His Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O BCYUHPXBHCUYBA-CUJWVEQBSA-N 0.000 claims description 4
- LAYSXAOGWHKNED-XPUUQOCRSA-N Val-Gly-Ser Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LAYSXAOGWHKNED-XPUUQOCRSA-N 0.000 claims description 4
- 108010017391 lysylvaline Proteins 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 3
- AYFVRYXNDHBECD-YUMQZZPRSA-N Asp-Leu-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AYFVRYXNDHBECD-YUMQZZPRSA-N 0.000 claims description 2
- ALMIMUZAWTUNIO-BZSNNMDCSA-N Asp-Tyr-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ALMIMUZAWTUNIO-BZSNNMDCSA-N 0.000 claims description 2
- MBPKYKSYUAPLMY-DCAQKATOSA-N Cys-Arg-Leu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O MBPKYKSYUAPLMY-DCAQKATOSA-N 0.000 claims description 2
- OGMQXTXGLDNBSS-FXQIFTODSA-N Glu-Ala-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O OGMQXTXGLDNBSS-FXQIFTODSA-N 0.000 claims description 2
- ADJWHHZETYAAAX-SRVKXCTJSA-N Leu-Ser-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N ADJWHHZETYAAAX-SRVKXCTJSA-N 0.000 claims description 2
- 229940126585 therapeutic drug Drugs 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- QSFHZPQUAAQHAQ-CIUDSAMLSA-N Asp-Ser-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O QSFHZPQUAAQHAQ-CIUDSAMLSA-N 0.000 claims 1
- 150000001945 cysteines Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 230000015572 biosynthetic process Effects 0.000 abstract description 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract description 8
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 7
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 208000035473 Communicable disease Diseases 0.000 abstract description 2
- 238000001228 spectrum Methods 0.000 abstract description 2
- 102000001189 Cyclic Peptides Human genes 0.000 abstract 1
- 108010069514 Cyclic Peptides Proteins 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 description 52
- 239000000243 solution Substances 0.000 description 20
- 239000002299 complementary DNA Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 241001476406 Hoplobatrachus tigerinus Species 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000003001 serine protease inhibitor Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 8
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 208000007882 Gastritis Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 206010033645 Pancreatitis Diseases 0.000 description 6
- 102000004142 Trypsin Human genes 0.000 description 6
- 108090000631 Trypsin Proteins 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 241000269435 Rana <genus> Species 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 102000012479 Serine Proteases Human genes 0.000 description 4
- 108010022999 Serine Proteases Proteins 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- DCQMJRSOGCYKTR-GHCJXIJMSA-N Ile-Asp-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O DCQMJRSOGCYKTR-GHCJXIJMSA-N 0.000 description 3
- CRNNMTHBMRFQNG-GUBZILKMSA-N Lys-Glu-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N CRNNMTHBMRFQNG-GUBZILKMSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- 229940122055 Serine protease inhibitor Drugs 0.000 description 3
- 101710102218 Serine protease inhibitor Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- -1 ABTS radical Chemical class 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- NNCSJUBVFBDDLC-YUMQZZPRSA-N Gly-Leu-Ser Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O NNCSJUBVFBDDLC-YUMQZZPRSA-N 0.000 description 2
- HIAHVKLTHNOENC-HGNGGELXSA-N His-Glu-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O HIAHVKLTHNOENC-HGNGGELXSA-N 0.000 description 2
- DLCOFDAHNMMQPP-SRVKXCTJSA-N Leu-Asp-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DLCOFDAHNMMQPP-SRVKXCTJSA-N 0.000 description 2
- NTBFKPBULZGXQL-KKUMJFAQSA-N Lys-Asp-Tyr Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NTBFKPBULZGXQL-KKUMJFAQSA-N 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 244000292697 Polygonum aviculare Species 0.000 description 2
- 235000006386 Polygonum aviculare Nutrition 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- KLGFILUOTCBNLJ-IHRRRGAJSA-N Tyr-Cys-Arg Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)O KLGFILUOTCBNLJ-IHRRRGAJSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 230000036632 reaction speed Effects 0.000 description 2
- 230000029865 regulation of blood pressure Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 108010048818 seryl-histidine Proteins 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000005760 tumorsuppression Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- LHTLDFWBUPYUDR-DUXPYHPUSA-N (2e)-3-(2,4-dichlorophenyl)-n-hydroxyacrylamide Chemical compound ONC(=O)\C=C\C1=CC=C(Cl)C=C1Cl LHTLDFWBUPYUDR-DUXPYHPUSA-N 0.000 description 1
- YDMBNDUHUNWWRP-VJBWXMMDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]piperidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C1=CC=CC=C1 YDMBNDUHUNWWRP-VJBWXMMDSA-N 0.000 description 1
- OCZVHBZNPVABKX-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine;ethanol Chemical compound CCO.[O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 OCZVHBZNPVABKX-UHFFFAOYSA-N 0.000 description 1
- CWNPOQFCIIFQDM-UHFFFAOYSA-N 3-nitrobenzyl alcohol Chemical compound OCC1=CC=CC([N+]([O-])=O)=C1 CWNPOQFCIIFQDM-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000340668 Bombina maxima Species 0.000 description 1
- 101000984722 Bos taurus Pancreatic trypsin inhibitor Proteins 0.000 description 1
- 241001415440 Bufo gargarizans Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000149140 Fejervarya limnocharis Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108010039286 S 2238 Proteins 0.000 description 1
- 240000000411 Sansevieria trifasciata Species 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000004362 fungal culture Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000012599 radical scavenging assay Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 238000010267 two-fold dilution method Methods 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Birds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to an active polypeptide, a gene thereof and application thereof in pharmacy, wherein the rana rugulosa protease inhibitory peptide is cyclic peptide consisting of 33 amino acids, the molecular weight is 3768.33 daltons, the isoelectric point is 6.303, the amino acid sequence is SEQ ID NO.1, and the third cysteine and the eighth cysteine of the polypeptide form an intramolecular disulfide bond. The gene sequence of the rana nigromaculata protease inhibitory peptide consists of SEQ ID NO.4, wherein the mature rana nigromaculata protease inhibitory peptide with the coding function is 379-477 nucleotide. The rana rugulosa protease inhibitory peptide has the characteristics of simple structure, convenient artificial synthesis, wide antibacterial spectrum and strong activity, and can be used for preparing medicaments for treating pathogenic microorganism infectious diseases and beautifying and caring skin medicaments.
Description
Technical Field
The invention relates to the field of biomedicine, in particular to a protein obtained from animal tissues.
Background
The most essential function of serine protease inhibitors (serpins) is to prevent proteolysis and to regulate the hydrolytic equilibrium of serine proteases. By regulating serine proteases, serine protease inhibitors have important effects on physiological and biochemical functions in organisms. For example, they play an important role in blood coagulation, complement formation, fibrinolysis, protein folding, cell migration, cell differentiation, cell matrix reconstitution, hormone formation and transport, intracellular proteolysis, blood pressure regulation, tumor suppression, and the development of viral or parasitic pathogenicity. Serine protease inhibitors regulate such numerous physiological processes that they have wide clinical application values, e.g., aprotinin is widely used clinically in the treatment of gastritis, pancreatitis, etc., and also in chest surgery for anti-fibrinolysis, inhibition of contact activation, anti-inflammation, etc. (Br J anasth.2013, 110(5): 675-8). Serine protease analogs such as Kallikrein and tryptase play an important role in the development of inflammatory diseases such as rheumatoid arthritis and rhinitis, conjunctivitis, asthma, gastroenteritis, and cardiovascular inflammation (Biol chem.2004,385(11): 989-96). Therefore, serine protease inhibitors have become hot spots in international research, and the research and development thereof imply great preparation value of clinical therapeutic drugs.
Amphibians have been the source of traditional pharmaceuticals. Amphibian animals such as Bufo gargarizans, Bombina maxima, Rana nigromaculata, and Rana nigromaculata (Euphlyctis limnocharis) are widely used as traditional Chinese medicinal materials in China. Modern research shows that: the skin and internal organs of these amphibians have a wide range of pharmacological activities, such as broad-spectrum antibacterial action, antitumor, local anesthesia, analgesia, immunomodulation, action on the cardiovascular system, etc. (Dongwuxue Yanjiu,2015,36(4): 183-222). The complexity of the traditional Chinese medicine components and the limitation of the processing method thereof cause that the active ingredients of the medicine can not play a better role, and the search of specific active monomer compounds from the traditional medicines is one of the important contents of the modernization of the traditional Chinese medicine. In foreign countries, the search for specific pharmacologically active monomeric compounds of amphibious skin has become a hot spot of new drug invention. A number of protease inhibitor polypeptides with a molecular weight of less than 10kDa have been identified from amphibian skin. These protease inhibitors of amphibian skin are functional in combating microbial infections in addition to their role in the processing and degradation of precursor proteins, and thus many of the protease inhibitors from amphibians have both antibacterial and protease inhibitor activity, including ranacyclin-B, KPHTI, HV-BBI, HJTI, hyllaserpin S2, OGTI, PYR, PSKP-1, PSKP-2, BOTI, BVTI, BMTI, BPTI, pLR and BSTI, etc. (Chem Rev. 2015176115 (4): 0-1846).
In addition, oxidative stress is considered to be associated with various diseases such as senile dementia, Parkinson's disease, which are caused by diabetes, complications caused by diabetes, rheumatoid arthritis and amyotrophic lateral sclerosis (Food Chemistry,2008,107, 1485-.
China has a long history of application of amphibian drugs, but researches on active ingredients and pharmacological properties of the amphibian drugs mainly focus on organic small molecules such as alkaloid and the like, and few researches on skin active peptide substances are carried out. Frog (Huwen)Hoplobatrachus_ rugulosus) Is one of the important economic frogs which are artificially fed, and the national level II focuses on protecting animals. At present, few studies on pharmacologically active substances for the skin are made.
Since the 21 st century, the rapid development of genomics and the rise of synthetic biology have greatly promoted the research on the structure and function of natural products; the invention is obtained by using a transcriptomics method and pharmacological researchGiant knotweed frog protease inhibiting peptideThe complete sequence amino acid structure is searched and compared by a protein database, and no identical polypeptide is found. The inventor will inventGiant knotweed frog protease inhibiting peptideThe coding genes are searched and compared by a gene database, and any identical gene is not found.
Disclosure of Invention
The invention aims to provide a rana rugulosa protease inhibiting peptide with broad-spectrum antimicrobial (including gram negative and gram positive bacteria, fungi and viruses), antioxidant and pancreatin inhibitor activities, a gene thereof and application thereof in preparing medicaments for treating pathogenic microorganism infectious diseases and beautifying and skin-care medicaments.
In order to solve the technical problems, the invention adopts the technical scheme that:
one aspect of the invention provides a rana rugulosa protease inhibitory peptide, wherein the sequence of the polypeptide is shown as SEQ ID No. 1.
KECKDYYCRLLMKVGSTSHIDSLDLGLSHEAQQ SEQ ID NO.1
The invention also provides a rana rugulosa protease inhibitory peptide, which is characterized by consisting of 33 amino acids, having a molecular weight of 3768.33 daltons, an isoelectric point of 6.303 and an amino acid sequence as follows: lys Glu Cys Lys Asp Tyr Tyr Cys Arg Leu Leu Met Lys Val Gly Ser Thr SerHis Ile Asp Ser Leu Asp Leu Gly Leu Ser His Glu Ala Gln Gln (KECKDYYCRLLMKVGSTSHIDSLDLGLSHEAQQ) (SEQ ID NO.1), the third cysteine and the eighth cysteine of which form an intramolecular disulfide bond.
In another aspect, the present invention provides a nucleotide sequence of a rana gherai protease inhibitory peptide gene, which is characterized in that: the cDNA consists of 480 nucleotides, and the sequence from the 5 'end to the 3' end of the cDNA is shown in SEQ ID NO. 4.
The 379-477 th nucleotide in the sequence codes the mature rana rugulosa protease inhibiting peptide with functions.
In yet another aspect, the present invention provides a nucleotide encoding the rana rugulosa protease inhibitory peptide of claim 1.
In another aspect, the invention provides application of the rana rugulosa protease inhibitory peptide in preparation of medicines for treating pathogenic microorganism infection diseases and beautifying and skin-care medicines.
In another aspect, the invention provides the application of the rana rugulosa protease inhibitory peptide in preparing free radical scavenging medicaments or cosmetic products.
In another aspect, the invention provides application of the rana rugulosa protease inhibitory peptide in preparation of an antioxidant drug or a cosmetic product.
In a further aspect of the invention, the rana nigromaculata protease inhibitory peptide is used for preparing a medicine for preventing or treating gastritis or pancreatitis, preferably, the gastritis or the pancreatitis is inflammation-related gastritis or inflammation-related pancreatitis.
In a further aspect the invention provides the use of the aforementioned rana gherai protease inhibitory peptides in inhibiting bacteria for non-diagnostic or therapeutic purposes, preferably the bacteria are escherichia coli, staphylococcus aureus, bacillus subtilis, pseudomonas aeruginosa and candida albicans.
In a further aspect, the invention provides the use of the rana nigromaculata protease inhibitory peptide in the preparation of a medicament or a cosmetic product for inhibiting bacteria, preferably escherichia coli, staphylococcus aureus, bacillus subtilis, pseudomonas aeruginosa and candida albicans.
The invention has the beneficial effects that:
the amino acid structure of the rana rugulosa protease inhibitory peptide is deduced from the rana rugulosa protease inhibitory peptide coding gene, and the synthesized rana rugulosa protease inhibitory peptide has obvious effects of inhibiting the growth of bacteria and fungi, inhibiting the activity of pancreatin and resisting oxidation. The rana rugulosa protease inhibitory peptide has the beneficial characteristics of simple structure, convenience in artificial synthesis, wide antibacterial spectrum and strong activity.
Drawings
FIG. 1 shows HPLC purification identification results of rana rugulosa protease inhibitory peptide of the present invention;
FIG. 2 shows the results of mass spectrometric identification of rana rugulosa protease inhibitory peptides of the present invention;
FIG. 3 shows the results of the activity of the peptide serine protease inhibitor of rana rugulosa protease inhibitor of the present invention;
FIG. 4 is a relation curve of the amount-effect of the rana rugulosa protease inhibitory peptide for eliminating DPPH and ABTS free radicals.
Detailed Description
The invention is described in further detail below with reference to the following figures and detailed description:
the rana rugulosa protease inhibitory peptide is a polypeptide consisting of 33 amino acids, has the molecular weight of 3768.33 daltons, the isoelectric point of 6.303 and the amino acid sequence of: lys Glu Cys Lys Asp TyrTyr Cys Arg Leu Leu Met Lys Val Gly Ser Thr Ser His Ile Asp Ser Leu Asp LeuGly Leu Ser His Glu Ala Gln Gln (KECKDYYCRLLMKVGSTSHIDSLDLGLSHEAQQ) (SEQ ID NO.1), the third cysteine and the eighth cysteine of which form an intramolecular disulfide bond to form a loop.
The 379-477 nucleotide code of the rana nigromaculata protease inhibitory peptide gene sequence SEQ ID NO. 4. The preparation process of the rana rugulosa protease inhibitory peptide and the gene thereof comprises the following steps:
example 1 cloning of a tiger frog protease inhibitory peptide gene:
I. extracting total RNA of rana rugulosa skin: cleaning living Rana rugulosa with water, placing into liquid nitrogen, quickly freezing for 4h, collecting skin tissue, weighing, collecting 300mg skin tissue, adding 10m1 total RNA extraction buffer (Trizol solution, product of GIBCOBRL company, USA), and homogenizing for 30min in 20m1 glass homogenizer. Adding equal volume of phenol/chloroform solution, mixing vigorously, standing at room temperature for 10min, centrifuging at 4 deg.C and 12000rpm for 10min, and removing precipitate. Adding isopropanol with the same volume into the supernatant, standing at room temperature for 10min, centrifuging at 12000rpm for 10min at 4 ℃, washing the precipitate with 75% ethanol once, and air drying to obtain the precipitate at the bottom of the tube, namely the total RNA of the rana rugulosa skin.
II. And (3) purifying the giant frog skin mRNA: the mRNA of the skin of tiger frog is separated and purified by PROMEGA of AmericamRNA Isolation Systems kit. The method comprises the following specific steps: dissolving 500 μ g of total RNA of Rana rugulosa skin in 500 μ l of DEPC water, placing in 65 deg.C water bath for 10min, adding 3 μ l of Oligo (dT) probe and 13 μ l of 20 XSSC solution, mixing, standing at room temperature, and cooling to obtain solution A. Mixing the magnetic beads, adsorbing with magnetic frame for 30S, discarding supernatant, adding 0.5 XSSC 0.3m1, adsorbing with magnetic frame for 30S, and adding 0.1ml 0.5 XSSC to suspend, and named as solution B. Adding solution A into solution B, standing at room temperature for 10min, adsorbing with magnetic frame for 30sec, discarding supernatant, washing with 0.1 XSSC for 4 times, discarding supernatant, adding 0.L DEPC water, suspending, adsorbing with magnetic frame for 30sec, transferring supernatant to new test tube, adding 0.15m1DEPC waterResuspending, adsorbing with magnetic frame for 30S, transferring supernatant to the test tube, and collecting the supernatant as purified skin mRNA of Rana rugulosa. 1/10 volumes of 3M sodium acetate, pH5.2 and an equal volume of isopropanol were added, the mixture was left at-70 ℃ for 30 minutes, centrifuged at 12000rpm for 10 minutes at 4 ℃, the supernatant was discarded, and the precipitate was dissolved in 10. mu.l of DEPC water to obtain the skin mRNA of Rana nigromaculata.
III, constructing a skin cDNA library of the tiger frog: a Kit was constructed using the plasmid cDNA library of the CreatorTM SMART TM cDNAlibrary Construction Kit of CLONTECH.
First strand cDNA Synthesis (reverse transcription of mRNA): mu.l of Rana rugulosa skin mRNA, 1. mu.l of SMART IV oligonucleotide, 1. mu.l of CDS III/3' PCR primer, and 2. mu.l of deionized water were added to a 0.5ml sterile centrifuge tube to make the total volume 5. mu.l. Mix the reagents in the centrifuge tubes and centrifuge at 12000rpm for 15sec, and incubate at 72 ℃ for 2 min. Centrifuge tubes were incubated on ice for 2 min. The following reagents 2.0. mu.l of 5 Xprimary strand buffer, 1.0. mu.l of 20mM dithiothreitol, 1.0. mu.l of 10mM dNTP mix, and 1.0. mu.l of PowerScript reverse transcriptase were added to the centrifuge tube. Mix the reagents in the centrifuge tubes and centrifuge at 12000rpm for 15sec, incubate at 42 ℃ for 1 h. The first strand synthesis was stopped by placing the centrifuge tube on ice. Mu.l of the first strand of the synthesized cDNA was taken from the centrifuge tube and used.
B. Amplifying the second strand by using a long-terminal polymerase chain reaction (LD-PCR) method: the PCR instrument was preheated to 95 ℃. Mu.l of the first strand of the cDNA (reverse transcription of mRNA), 80. mu.l of deionized water, 10. mu.l of 10 × Advantage 2PCR buffer, 2. mu.l of a 50 × dNTP mix, 2. mu.l of a 5 'PCR primer, 2. mu.l of a CDS III/3' PCR primer, and 2. mu.l of an E.coli polymerase centrifuge tube were reacted. Amplification was performed in a PCR instrument according to the following procedure: 20sec at 95 ℃, 5sec at 95 ℃, 6min at 68 ℃ and 22 cycles. After the circulation was completed, the double strand cDNA synthesized in the centrifuge tube was extracted.
PCR products from PROMEGAThe SV Gel and PCR Clean-Up System kit is extracted and recovered, and the steps are as follows: adding cDNA double chain obtained by PCR into equal volume of membrane combined buffer, reversing and mixing, transferring the mixture into a centrifugal purification column, standing at room temperature for 5minAnd (5) fully combining the DNA with the silica gel membrane. The collection tube was centrifuged at 12000rpm for 30sec to discard the waste liquid. Add 700. mu.l of eluent (containing ethanol) to the centrifugation and purification column, centrifuge at 12000rpm for 30sec, and discard the waste liquid from the collection tube. And repeating the steps. Centrifuge at 12000rpm for 5 min. The centrifugal purification column was placed in a new centrifuge tube. 30. mu.l of ultrapure water was added thereto, and the mixture was allowed to stand at room temperature for 5 min. Centrifuging at 12000rpm for 30sec, and obtaining the purified cDNA double strand in the bottom of the tube.
D. Adding 1 mul Takara pMD18-T vector and 4 mul tiger frog cDNA double-chain solution into a microcentrifuge tube, adding 5 mul ligase buffer mixture, reacting at 16 ℃ for 2h, adding 10 mul into 100 mul DH5 α competent cells, placing in ice for 30min, heating at 42 ℃ for 90Sec, placing in ice for 1 min, adding LB culture medium 890 mul incubated at 37 ℃, slowly shaking for culturing at 37 ℃ for 60min, taking 200 mul LB culture medium coated on X-Gal, IPTG and Amp, culturing at 37 ℃ for 16h to form single colonies, washing colonies with 5m1LB liquid culture medium on each dish, adding 30% glycerol, freezing, and storing the constructed cDNA about 1 × 106Individual clones.
IV, cloning and screening the rana rugulosa protease inhibitory peptide gene: the amplification primer is 25 nucleotides in length and has a sequence of 5 'ATGAAGGTCTGGCAGTGCGCGCTC 3' (SEQ ID NO.2), and another amplification primer in PCR is SMART (CLONTECH Co., Ltd.)TM3 ' PCR Primer in cDNA Library Construction Kit, the sequence is 5 ' ATTCTAGAGGCCGAGGCGGCCGACATG 3 ' (SEQ ID NO. 3). The PCR reaction was performed under the following conditions: 30sec at 94 ℃, 45sec at 50 ℃ and 2.5min at 72 ℃ for 35 cycles.
The constructed bacterial cDNA library was first titrated, then diluted to the appropriate bacterial concentration with LB medium containing 100. mu.g/ml ampicillin (approximately 5000 bacteria/ml and 30 bacteria/ml for the first round of selection and the second round of selection, respectively), plated in an 8X 8 matrix (64 wells in total, 100. mu.1 per well) on 96-well plates, and incubated overnight at 37 ℃. And respectively combining the bacterial culture solutions according to rows and columns, carrying out PCR identification on 16 samples, and carrying out second round screening on the bacteria samples with the crossed positive holes.
V, determining the gene sequence of the tiger frog protease inhibitory peptide and obtaining the results: plasmid DNA extraction nucleotide sequences were determined by dideoxy using an apparatus, US Applied Biosystems 373A full-automatic nucleotide sequencer, Sequencing primers were BcaBESTTM Sequencing Primer RV-M and BcaBESTTM Sequencing Primer M13-47, BcaBESTTM Sequencing Primer RV-M sequences: 5 'GAGCGGATAACAATTTCACACAGG 3' (SEQ ID NO.5), BcaBESTTM Sequencing Primer M13-47: 5 'CGCCAGGGTTTTCCCAGTCACGAC 3' (SEQ ID NO. 6). The sequence from 5 'end to 3' end of the gene sequencing result is (SEQ ID NO.4):
the sequence table of the tiger frog protease inhibitory peptide gene nucleotide is as follows: the sequence length is 480 bases; sequence types: a nucleic acid; number of chains: single-stranded; topology: straight-chain; the sequence types are as follows: cDNA; the source is as follows: skin of tiger frog.
The gene of the rana rugulosa protease inhibitory peptide is used for deducing that the mature active multifunctional protease inhibitory peptide with the function is 379-477 th nucleotide and has the amino acid sequence as follows: KECKDYYCRLLMKVGSTSHIDSLDLGLSHEAQQ (see sequence SEQID NO.1)
Example 2 preparation of rana rugulosa protease inhibitory peptides:
i, a preparation method of rana rugulosa protease inhibitory peptide: the amino acid sequence of the mature multifunctional protease inhibitory peptide with the coding function is deduced according to the gene of the rana gherai protease inhibitory peptide, and then the polypeptide is synthesized by an automatic polypeptide synthesizer. Desalting by HPLC reverse phase C18 column chromatography, and purifying. The formation of disulfide bonds was carried out by air oxidation, specifically by dissolving the polypeptide in 0.1mg/ml in 0.1% acetic acid solution in a flask, titrating to pH 7.8 with ammonium hydroxide, and stirring overnight at room temperature. Desalting by HPLC reverse phase C18 column chromatography, and purifying. The purification was carried out with a solution A of 0.05% TFA + 2% CH3CN, a solution B of 0.05% TFA + 90% CH3CN, a concentration gradient of 25-40% in 15min, a detection wavelength of 220nm, and the presence of the polypeptide at 9.248 min.
II, measuring the molecular weight by adopting a Fast atom bombardment mass spectrometry (FAB-MS), taking glycerol, m-nitrobenzyl alcohol, dimethyl sulfoxide (1:1: l, V: V: V, volume ratio) as a substrate, taking Cs + as a bombardment particle, and taking the current as 1 muA and the emission voltage as 25 Kv.
III, identifying the purity of the purified rana rugulosa protease inhibitory peptide by using a High Performance Liquid Chromatography (HPLC) method, determining an isoelectric point by using isoelectric focusing electrophoresis, and determining an amino acid sequence structure by using an automatic amino acid sequencer.
The tiger frog protease inhibitory peptide is a polypeptide encoded by China amphibian tiger frog protease inhibitory peptide gene, has the molecular weight of 3768.33 daltons, the isoelectric point of 6.303 and the amino acid sequence of: lys Glu Cys Lys Asp Tyr TyrCys Arg Leu Leu Met Lys Val Gly Ser Thr Ser His Ile Asp Ser Leu Asp Leu GlyLeu Ser His Glu Ala Gln Gln (KECKDYYCRLLMKVGSTSHIDSLDLGLSHEAQQ) (SEQ ID NO.1), the third cysteine and the eighth cysteine of which form an intramolecular disulfide bond.
Example 3 Activity assay of Rana rugulosa protease inhibitory peptides
I, determination of antibacterial ability
The antibacterial activity is detected by adopting a cup-dish method, the bacterial culture adopts a common agar culture medium, and the fungal culture adopts a modified Sabouraud (Sabousand) culture medium. Respectively injecting 20ml of the heated and melted culture medium into the flat dishes to serve as a bottom layer, uniformly spreading the culture medium in the dish bottoms, solidifying, heating and melting another proper amount of the culture medium, respectively adding 5ml of bacterial suspension into each dish, and uniformly shaking to uniformly spread the culture medium on the bottom layer to serve as a bacterial layer. After cooling, 6 sterilized stainless steel cups were placed in a dish at equal distances. Adding 0.3mg/ml sample solution to be measured into the first steel cup, adding 0.l ml sample solution into the other steel cups by a two-fold dilution method, culturing at 37 ℃, and observing the size of the inhibition zone after 24-48 h. The inhibition zone l0mm or more is defined as the Minimum Inhibition Concentration (MIC). All the tested strains are from Guangdong microbiological research institute, the test is repeated for four times, the average value is taken, the result is shown in table 1, the rana nigromaculata protease inhibitory peptide has obvious inhibitory action on escherichia coli, staphylococcus aureus, bacillus subtilis, pseudomonas aeruginosa and candida albicans, and the rana nigromaculata protease inhibition has good broad-spectrum bacterial growth inhibition effect.
TABLE 1 antibacterial Activity of rana rugulosa protease inhibitory peptides
II, determination of serine protease inhibitor Activity
Varying amounts of rana gheraria protease inhibiting peptide were dissolved in 0.05M Tris-HCl buffer and a certain amount of trypsin (final concentration 40. mu.g/ml) in 0.05M Tris-HCl buffer at room temperature for 2min, and the reaction was initiated by addition of chromogenic substrate S-2238 (final concentration 40. mu.g/ml), followed by monitoring the change in absorbance for 2min using a spectrophotometer manufactured by PERKIN ELMER (USA), and addition of the same volume of 0.05M Tris-HCl buffer with a blank, and the inhibition constant Ki ═ I/(V0/VI + 1). [I] The molar concentration of the tiger frog protease inhibitory peptide is shown, V0 is blank control and is the reaction speed of trypsin and chromogenic substrate, and V1 is the reaction speed of trypsin and chromogenic substrate after the tiger frog protease inhibitory peptide is added. This experiment was repeated six times and the average was taken.
As shown in FIG. 3, the concentration of the peptide inhibiting sansevieria trifasciata protease required for inhibiting the activity of half of trypsin was 0.368. mu.M, and the inhibition constant Ki against trypsin was 3.2X 10-7M。
Serine protease inhibitors have important effects on physiological and biochemical functions in organisms. For example, they play an important role in blood coagulation, complement formation, fibrinolysis, protein folding, cell migration, cell differentiation, cell matrix reconstitution, hormone formation and transport, intracellular proteolysis, blood pressure regulation, tumor suppression, and the development of viral or parasitic pathogenicity. The rana rugulosa protease inhibiting peptide can effectively inhibit trypsin, and is proved to be capable of regulating a plurality of physiological processes in vivo and to have wide clinical application value. The pathogenesis of gastritis and pancreatitis involves the hydrolysis of many serine proteases, so inhibiting the hydrolysis of these enzymes can prevent the disease and reduce the subsequent damage of inflammatory factors to the body. The rana rugulosa protease inhibitory peptide with serine protease inhibitor activity can be applied to gastritis and pancreatitis related to inflammation.
III, determination of antioxidant Capacity
1) Determination of DPPH radical scavenging Capacity
Antioxidant polypeptides were studied using DPPH (1, 1-diphenylyl-2-picryl-hydrzyl) free radical scavenging assay. Preparing a DPPH ethanol solution with the concentration of 1 multiplied by 10 < -5 > mol/L, and storing the solution in a dark place. 2ml of 0.1mM solution of DPPH in absolute ethanol are added to a clean tube containing 2ml of the different enzymatic samples and mixed well. After standing at room temperature for 30min, absorbance at 517nm was measured, and the smaller the absorbance, the stronger the radical scavenging ability was.
Clearance (%) ═ 1- (a)i-Aj)/A0】*100%
In the formula, A02ml,0.1mM DPPH in absolute ethanol +2ml of sample reagent, blank, Ai2ml,0.1mM DPPH in absolute ethanol +2ml of sample, Aj2ml of absolute ethanol +2ml of sample.
2) Determination of ABTS free radical scavenging Activity
Dissolving ABTS with deionized water to make ABTS concentration reach 7mmol/L, adding potassium persulfate to make potassium persulfate concentration be 2.45 nmol/L. The solution was then left overnight at room temperature for 12-16 h in the dark. The resultant ABTS radical solution was diluted with phosphate buffer (PBS, 0.2mol/L, pH 7.4) to give an absorbance of 0.70 at 734 nm. 0.1ml of the enzymatic hydrolysate was mixed with 2.9ml of ABTS free radical solution, shaken for 30 seconds, reacted in the dark for 10 minutes, and then the absorbance of the reaction solution was measured at 734 nm. Distilled water is used as a blank to replace hydrolysate.
Clearance (%) ═ ai-Aj)/A0*100%
In the formula, A02.9ml of ABTS reagent was mixed with 0.1ml of distilled waterAbsorbance of the liquid, AjThe absorbance was 2.9ml ABTS +0.1ml enzymolysis solution mixture.
As shown in fig. 4, the rana gherai protease inhibitory peptide can significantly scavenge DPPH and ABTS free radicals. Free radical oxidation plays an important role in neurodegenerative diseases caused by senile dementia, Parkinson's disease, diabetes, rheumatoid arthritis and amyotrophic lateral sclerosis. The rana rugulosa protease inhibitory peptide can well remove free radicals, so that the rana rugulosa protease inhibitory peptide can be applied to treatment of related diseases caused by free radical oxidation. In addition, in order to prevent damage to the skin caused by free radicals, it is essential to add a free radical scavenger to a cosmetic skin care product. Therefore, the rana rugulosa protease inhibiting peptide can also be applied to beauty skin care products.
Claims (7)
1. The rana rugulosa protease inhibiting peptide is characterized by consisting of 33 amino acids, wherein the molecular weight of the rana rugulosa protease inhibiting peptide is 3768.33 daltons, the isoelectric point of the rana rugulosa protease inhibiting peptide is 6.303, and the amino acid sequence SEQ ID number 1 of the rana rugulosa protease inhibiting peptide is: lysglucyslys Asp Tyr Tyr Cys Arg Leu Leu Met Lys Val Gly Ser Thr Ser His Ile Asp SerLeu Asp Leu Gly Leu Ser His Glu Ala Gln Gln; the third and eighth cysteines of the polypeptide form an intramolecular disulfide bond.
2. A nucleotide encoding the rana rugulosa protease inhibitory peptide of claim 1.
3. Use of rana nigromaculata protease inhibitory peptide according to claim 1 for the preparation of a therapeutic drug and a cosmetic skin care drug for pathogenic microorganism infection diseases selected from escherichia coli, staphylococcus aureus, bacillus subtilis, pseudomonas aeruginosa and candida albicans.
4. Use of the rana rugulosa protease inhibitory peptide of claim 1 in the preparation of a free radical scavenging medicament or a free radical scavenging cosmetic product.
5. Use of the rana rugulosa protease inhibitory peptide of claim 1 in the preparation of an antioxidant drug or an antioxidant cosmetic product.
6. Use of a rana nigromaculata protease inhibiting peptide according to claim 1 for inhibiting bacteria, which are escherichia coli, staphylococcus aureus, bacillus subtilis, pseudomonas aeruginosa and candida albicans, for non-diagnostic or therapeutic purposes.
7. Use of the rana nigromaculata protease inhibitory peptide of claim 1 for the preparation of a medicament or cosmetic product for inhibiting bacteria, such as escherichia coli, staphylococcus aureus, bacillus subtilis, pseudomonas aeruginosa, and candida albicans.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610915371.1A CN106478811B (en) | 2016-10-20 | 2016-10-20 | Giant knotweed frog protease inhibitory peptide, gene thereof and application thereof in pharmacy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610915371.1A CN106478811B (en) | 2016-10-20 | 2016-10-20 | Giant knotweed frog protease inhibitory peptide, gene thereof and application thereof in pharmacy |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106478811A CN106478811A (en) | 2017-03-08 |
CN106478811B true CN106478811B (en) | 2020-04-17 |
Family
ID=58271054
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610915371.1A Expired - Fee Related CN106478811B (en) | 2016-10-20 | 2016-10-20 | Giant knotweed frog protease inhibitory peptide, gene thereof and application thereof in pharmacy |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106478811B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107513100A (en) * | 2017-10-19 | 2017-12-26 | 南方医科大学 | Mercuric chloride antibacterial peptide and its gene and application |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1883703A (en) * | 2006-05-30 | 2006-12-27 | 中国科学院昆明动物研究所 | Serine protease inhibitor of Rana grahami, its gene and application |
CN104558121A (en) * | 2014-12-31 | 2015-04-29 | 常熟理工学院 | Tiger frog antibacterial peptide, and coding gene and application thereof |
-
2016
- 2016-10-20 CN CN201610915371.1A patent/CN106478811B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1883703A (en) * | 2006-05-30 | 2006-12-27 | 中国科学院昆明动物研究所 | Serine protease inhibitor of Rana grahami, its gene and application |
CN104558121A (en) * | 2014-12-31 | 2015-04-29 | 常熟理工学院 | Tiger frog antibacterial peptide, and coding gene and application thereof |
Non-Patent Citations (2)
Title |
---|
Trypsin inhibitory loop is an excellent lead structure to design serine protease inhibitors and antimicrobial peptides;Li 等;《The FASEB Journal》;20070930;第21卷(第10期);第2466-2473页 * |
虎纹蛙皮肤组织cDNA文库的构建及抗菌肽基因tigerinin-HRs的克隆;王辉 等;《华北农学报》;20100228;第25卷(第1期);第61-67页 * |
Also Published As
Publication number | Publication date |
---|---|
CN106478811A (en) | 2017-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015161820A1 (en) | Amphiphilic synthetic antimicrobial peptide, and pharmaceutical composition and use thereof | |
CA2325658A1 (en) | Gene coding for heliomicine and use thereof | |
Luo et al. | A novel NK-lysin in hybrid crucian carp can exhibit cytotoxic activity in fish cells and confer protection against Aeromonas hydrophila infection in comparison with Carassius cuvieri and Carassius auratus red var | |
CA2776883A1 (en) | Antimicrobial and antibiofilm activity of cathelicidins | |
Kim et al. | Purification and characterization of antimicrobial peptides from the skin secretion of Rana dybowskii | |
CN106478811B (en) | Giant knotweed frog protease inhibitory peptide, gene thereof and application thereof in pharmacy | |
CN106432483B (en) | Rana chensinensis skin serine protease inhibitory peptide, gene and pharmaceutical application thereof | |
CN100581584C (en) | Serine protease inhibitor of Rana grahami, and its application | |
CN113527461B (en) | Horseshoe head bats source antibacterial peptide RF-CATH1 and application thereof | |
CN106496317B (en) | Rana chensinensis secretory peptide, gene thereof and application thereof in pharmacy | |
CN101570760B (en) | Recombinant mouse beta-alexin 3 polypeptide, preparation and use thereof | |
KR102146935B1 (en) | Poecilocorisin-1 peptide isolated from Poecilocoris lewisi or antimicrobial, antimycotic and antiinflammatory composition comprising it | |
CN106397564B (en) | Black-frame toad antioxidant peptide, gene thereof and application thereof in pharmacy | |
CN107501395B (en) | Rana nigromaculata antioxidant peptide, gene and application thereof | |
CN101186646A (en) | Application of king cobra toxin protease inhibitor and its derivatives | |
CN107513100A (en) | Mercuric chloride antibacterial peptide and its gene and application | |
CN113480628B (en) | Guizhou wart mud eel polypeptide TK-CATH and coding gene and application thereof | |
KR20130105545A (en) | A USE OF RORα FOR CONTROLLING ACTIVITY OF TH17 CELL | |
CN100389125C (en) | Rana grahami propyl sperm peptide, gene and variant and its pharmaceutical use | |
KR102146937B1 (en) | Tenoderasin-1 peptide isolated from Tenodera sinensis or antimicrobial, antimycotic and antiinflammatory composition comprising it | |
CN106432459A (en) | Microhyla pulchra antibacterial peptide, and gene thereof and application thereof in pharmacy | |
WO2023109991A1 (en) | Antimicrobial peptides derived from human ameloblastin protein, effective on microbial biofilms | |
JP2005508151A (en) | Mekuna eel caterin-related antimicrobial peptides and genes | |
KR20050072337A (en) | Analogues of antimicrobial peptide synthesized and produced from gaegurin 5 | |
Li | Identification and bioactivity evaluation of a novel peptide from the skin secretion of Pelophylax kl. esculentus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200417 |